InsiderClue
Stocks · Health care · Pharmaceutical Preparations

Dianthus Therapeutics, Inc.

DNTH Clue Score33
United States Fiscal year ends December CIK 0001690585 Results filed 4 Nov 2026
Add to watchlist

What the insiders did Net buying

Individual transactions

121
Insider
Date
Role
Action
Shares
Price
Amount
Edward Carr
17 Sep 2026
Chief Accounting Officer
Sold after exercise
700
$104.39
$73.07K
Edward Carr
17 Sep 2026
Chief Accounting Officer
Sold after exercise
1,100
$103.20
$113.52K
Edward Carr
17 Sep 2026
Chief Accounting Officer
Sold after exercise
3,501
$102.39
$358.47K
Edward Carr
17 Sep 2026
Chief Accounting Officer
Sold after exercise
6,771
$101.37
$686.38K
Edward Carr
17 Sep 2026
Chief Accounting Officer
Sold after exercise
7,928
$100.43
$796.21K
Simrat Randhawa
1 Sep 2026
EVP, Head of R&D
Sold after exercise
13,309
$106.74
$1.42M
Simrat Randhawa
1 Sep 2026
EVP, Head of R&D
Sold after exercise
7,215
$106.25
$766.59K
Simrat Randhawa
1 Sep 2026
EVP, Head of R&D
Sold after exercise
2,600
$105.19
$273.49K
Simon Read
19 Aug 2026
Director
Sold after exercise
2,778
$117.55
$326.55K
Adam M Veness
13 Aug 2026
SVP, General Counsel and Sec.
Exercised, kept
15,000
$18.17
$272.55K
Adam M Veness
10 Aug 2026
SVP, General Counsel and Sec.
Sold after exercise
16,167
$110.38
$1.78M
Simon Read
10 Aug 2026
Director
Sold after exercise
397
$111.77
$44.37K
Simon Read
10 Aug 2026
Director
Sold after exercise
470
$111.05
$52.19K
Simon Read
10 Aug 2026
Director
Sold after exercise
272
$109.96
$29.91K
Simon Read
10 Aug 2026
Director
Sold after exercise
831
$108.95
$90.54K
Simon Read
10 Aug 2026
Director
Sold after exercise
737
$108.17
$79.72K
Simon Read
10 Aug 2026
Director
Sold after exercise
70
$107.11
$7.50K
Anne McGeorge
10 Aug 2026
Director
Sold after exercise
700
$111.41
$77.99K
Anne McGeorge
10 Aug 2026
Director
Sold after exercise
1,000
$110.64
$110.64K
Anne McGeorge
10 Aug 2026
Director
Sold after exercise
1,800
$109.30
$196.74K
Anne McGeorge
10 Aug 2026
Director
Sold after exercise
2,800
$108.38
$303.46K
Anne McGeorge
10 Aug 2026
Director
Sold after exercise
1,450
$107.58
$155.99K
Marino Garcia
7 Aug 2026
CEO and President
Sold after exercise
21,909
$108.72
$2.38M
Marino Garcia
7 Aug 2026
CEO and President
Sold after exercise
104,091
$107.96
$11.24M
Marino Garcia
7 Aug 2026
CEO and President
Sold after exercise
800
$110.76
$88.61K
Marino Garcia
7 Aug 2026
CEO and President
Sold after exercise
2,536
$110.02
$279.01K
Marino Garcia
7 Aug 2026
CEO and President
Sold after exercise
2,373
$109.10
$258.89K
Marino Garcia
7 Aug 2026
CEO and President
Sold after exercise
23,907
$108.05
$2.58M
Marino Garcia
7 Aug 2026
CEO and President
Sold after exercise
10,384
$107.49
$1.12M
Adam M Veness
7 Aug 2026
SVP, General Counsel and Sec.
Sold after exercise
616
$111.18
$68.49K
Adam M Veness
7 Aug 2026
SVP, General Counsel and Sec.
Sold after exercise
3,217
$110.61
$355.83K
Ryan Savitz
9 Jul 2026
EVP, CFO & Cbo
Sold after exercise
5,566
$101.97
$567.57K
Ryan Savitz
9 Jul 2026
EVP, CFO & Cbo
Sold after exercise
15,329
$101.24
$1.55M
Ryan Savitz
9 Jul 2026
EVP, CFO & Cbo
Sold after exercise
10,354
$100.22
$1.04M
Adam M Veness
17 Jun 2026
SVP, General Counsel and Sec.
Sold after exercise
13,229
$81.38
$1.08M
Adam M Veness
17 Jun 2026
SVP, General Counsel and Sec.
Sold after exercise
16,771
$80.34
$1.35M
Simrat Randhawa
1 Jun 2026
EVP, Head of R&D
Sold after exercise
4,159
$91.37
$380.01K
Simrat Randhawa
1 Jun 2026
EVP, Head of R&D
Sold after exercise
16,943
$90.72
$1.54M
Simrat Randhawa
1 Jun 2026
EVP, Head of R&D
Sold after exercise
5,428
$89.72
$487.00K
Paula Soteropoulos
8 May 2026
Director
Sold after exercise
599
$85.47
$51.20K
Ryan Savitz
9 Apr 2026
EVP, CFO & Cbo
Sold after exercise
8,224
$89.84
$738.84K
Paula Soteropoulos
31 Mar 2026
Director
Sold after exercise
599
$80.11
$47.99K
Ryan Savitz
31 Mar 2026
EVP, CFO & Cbo
Sold after exercise
7,232
$85.54
$618.63K
Ryan Savitz
31 Mar 2026
EVP, CFO & Cbo
Sold after exercise
19,469
$84.57
$1.65M
Ryan Savitz
31 Mar 2026
EVP, CFO & Cbo
Sold after exercise
59,800
$83.90
$5.02M
Ryan Savitz
31 Mar 2026
EVP, CFO & Cbo
Sold after exercise
2,366
$82.84
$196.00K
Ryan Savitz
31 Mar 2026
EVP, CFO & Cbo
Sold after exercise
800
$81.36
$65.09K
Ryan Savitz
31 Mar 2026
EVP, CFO & Cbo
Sold after exercise
1,485
$80.25
$119.17K
Ryan Savitz
31 Mar 2026
EVP, CFO & Cbo
Sold after exercise
21,825
$78.86
$1.72M
Ryan Savitz
31 Mar 2026
EVP, CFO & Cbo
Sold after exercise
1,390
$78.33
$108.88K
Paula Soteropoulos
24 Mar 2026
Director
Sold after exercise
27,594
$78.05
$2.15M
Marino Garcia
16 Mar 2026
CEO and President
Exercised, kept
5,592
$17.88
$99.98K
Marino Garcia
16 Mar 2026
CEO and President
Exercised, kept
59,700
$6.70
$399.99K
Simrat Randhawa
12 Mar 2026
EVP, Head of R&D
Sold after exercise
33,830
$81.48
$2.76M
Edward Carr
12 Mar 2026
Chief Accounting Officer
Sold after exercise
300
$85.53
$25.66K
Edward Carr
12 Mar 2026
Chief Accounting Officer
Sold after exercise
200
$83.38
$16.68K
Edward Carr
12 Mar 2026
Chief Accounting Officer
Sold after exercise
3,865
$82.66
$319.48K
Edward Carr
12 Mar 2026
Chief Accounting Officer
Sold after exercise
23,465
$81.75
$1.92M
Edward Carr
12 Mar 2026
Chief Accounting Officer
Sold after exercise
15,852
$80.71
$1.28M
Marino Garcia
12 Mar 2026
CEO and President
Sold after exercise
900
$85.53
$76.98K
Marino Garcia
12 Mar 2026
CEO and President
Sold after exercise
200
$83.38
$16.68K
Marino Garcia
12 Mar 2026
CEO and President
Sold after exercise
12,796
$82.60
$1.06M
Marino Garcia
12 Mar 2026
CEO and President
Sold after exercise
65,517
$81.74
$5.36M
Marino Garcia
12 Mar 2026
CEO and President
Sold after exercise
43,505
$80.69
$3.51M
Ryan Savitz
4 Dec 2025
CFO & Cbo
Sold after exercise
20,000
$45.18
$903.60K
Simrat Randhawa
14 Nov 2025
EVP, Head of R&D
Sold after exercise
109,031
$38.14
$4.16M
Simrat Randhawa
13 Nov 2025
EVP, Head of R&D
Sold after exercise
18,576
$37.72
$700.69K
Simrat Randhawa
13 Nov 2025
EVP, Head of R&D
Sold after exercise
42,765
$37.04
$1.58M
Simrat Randhawa
13 Nov 2025
EVP, Head of R&D
Sold after exercise
26,166
$35.80
$936.74K
Ryan Savitz
9 Sep 2025
CFO & Cbo
Sold after exercise
20,000
$35.00
$700.00K
Fairmount Funds Management LLC
29 Sep 2023
Director
Buy indirect
24,670
$13.63
$336.25K
Fairmount Funds Management LLC
26 Sep 2023
Director
Buy indirect
30,000
$13.15
$394.50K
Simrat Randhawa
22 Sep 2023
Chief Medical Officer
Buy
2,000
$13.20
$26.40K
Simrat Randhawa
21 Sep 2023
Chief Medical Officer
Buy
2,000
$13.20
$26.40K
Fairmount Funds Management LLC
19 Sep 2023
Director
Buy indirect
30,000
$13.20
$396.00K
Fairmount Funds Management LLC
13 Sep 2023
Director
Buy indirect
9,367
$11.76
$110.16K
Fairmount Funds Management LLC
12 Sep 2023
Director
Buy indirect
14,887
$10.85
$161.52K
Third Rock Ventures IV, L.P.
8 Feb 2023
10% owner
Sell
1,500,000
$0.82
$1.23M
Third Rock Ventures IV, L.P.
7 Feb 2023
10% owner
Sell
2,200,000
$0.83
$1.83M
David Wayne Nichols
16 Sep 2021
Chief Technical Officer
Sell
5,694
$6.73
$38.32K
Lisa Olson
16 Sep 2021
See Remarks
Sell
5,736
$6.73
$38.60K
Thomas W. Beetham
16 Sep 2021
See Remarks
Sell
6,103
$6.73
$41.07K
Jason Gardner
16 Sep 2021
See Remarks
Sell
14,340
$6.73
$96.51K
Caren Deardorf
16 Sep 2021
Chief Commercial Officer
Sell
6,238
$6.73
$41.98K
Stephen F. Mahoney
16 Sep 2021
See Remarks
Sell
5,736
$6.73
$38.60K
Kristen Stants
16 Sep 2021
Chief People Officer
Sell
5,736
$6.73
$38.60K
Bruce Booth
29 Jun 2020
Director
Buy indirect
1,250,000
$8.00
$10.00M
Jason Gardner
10 Jan 2020
See Remarks
Sell
11,200
$15.25
$170.80K
Jason Gardner
2 Jan 2020
See Remarks
Sell
2,800
$15.10
$42.28K
John C. Davis Jr
2 Jan 2020
Chief Medical Officer
Sold after exercise
11,294
$15.04
$169.82K
Zoran Zdraveski
24 Dec 2019
See Remarks
Sell
7,902
$16.00
$126.43K
Christina K. Isacson
24 Dec 2019
Chief Business Officer
Sell
4,463
$16.01
$71.45K
Jason Gardner
23 Dec 2019
See Remarks
Sell
2,897
$15.10
$43.75K
Christina K. Isacson
23 Dec 2019
Chief Business Officer
Sell
9,867
$16.03
$158.17K
Zoran Zdraveski
23 Dec 2019
See Remarks
Sell
4,181
$16.03
$67.02K
John C. Davis Jr
20 Dec 2019
Chief Medical Officer
Sold after exercise
919
$15.00
$13.79K
Jason Gardner
20 Dec 2019
See Remarks
Sell
76,711
$15.16
$1.16M
John C. Davis Jr
10 Dec 2019
Chief Medical Officer
Sold after exercise
17,055
$15.00
$255.83K
Jason Gardner
10 Dec 2019
See Remarks
Sell
4,392
$15.10
$66.32K
John C. Davis Jr
9 Dec 2019
Chief Medical Officer
Sold after exercise
4,614
$15.00
$69.21K
Michael P. Cooke
2 Dec 2019
Chief Scientific Officer
Sell
2,500
$13.21
$33.04K
Michael P. Cooke
2 Dec 2019
Chief Scientific Officer
Sell
1,373
$13.31
$18.28K
Michael P. Cooke
2 Dec 2019
Chief Scientific Officer
Sell
3,627
$12.74
$46.20K
Michael P. Cooke
20 Nov 2019
Chief Scientific Officer
Sell
5,000
$12.00
$60.00K
Michael P. Cooke
1 Nov 2019
Chief Scientific Officer
Sell
5,000
$10.67
$53.33K
Michael P. Cooke
1 Oct 2019
Chief Scientific Officer
Sell
5,000
$10.01
$50.06K
Michael P. Cooke
19 Sep 2019
Chief Scientific Officer
Sell
1,656
$12.00
$19.87K
Michael P. Cooke
12 Sep 2019
Chief Scientific Officer
Sell
844
$12.00
$10.13K
Michael P. Cooke
3 Sep 2019
Chief Scientific Officer
Sell
5,000
$10.11
$50.53K
Michael P. Cooke
1 Aug 2019
Chief Scientific Officer
Sell
2,500
$13.41
$33.52K
Michael P. Cooke
1 Aug 2019
Chief Scientific Officer
Sell
5,000
$13.42
$67.11K
Michael P. Cooke
1 Jul 2019
Chief Scientific Officer
Sell
2,500
$14.42
$36.05K
Michael P. Cooke
1 Jul 2019
Chief Scientific Officer
Sell
5,000
$14.39
$71.93K
Jason Gardner
21 Jun 2019
See Remarks
Sell
12,331
$15.11
$186.32K
Christina K. Isacson
21 Jun 2019
Chief Business Officer
Sell
5,415
$16.07
$87.02K
Jason Gardner
20 Jun 2019
See Remarks
Sell
1,669
$15.10
$25.20K
Michael P. Cooke
17 Jun 2019
Chief Scientific Officer
Sell
7,500
$13.90
$104.27K
Bruce Booth
20 Mar 2019
Director
Sell indirect
14,245
$17.86
$254.42K
Atlas Venture Fund X, L.P.
20 Mar 2019
10% owner
Sell indirect
14,245
$17.86
$254.42K
Jason Gardner
25 Jun 2018
See Remarks
Buy
400
$15.00
$6.00K
David Scadden
25 Jun 2018
Director
Buy
6,600
$15.00
$99.00K

What was left out

Form 4 filings counted 242
Amendments (4/A) skipped 2
Filings about a different issuer 0
Unreadable filings 0
Joint filings 16
Sales on a Rule 10b5-1 plan 0
Sales straight out of an exercise 71
Sales at will 37
Transactions with no price 0
Shares from compensation/vesting 32,438,229
Sales filed before the plan box existed 37
History held since 27 Jun 2018